FI4455140T3 - Glp-1-reseptoriagonistin kiteisiä muotoja ja niiden valmistusmenetelmiä - Google Patents

Glp-1-reseptoriagonistin kiteisiä muotoja ja niiden valmistusmenetelmiä

Info

Publication number
FI4455140T3
FI4455140T3 FIEP22910190.2T FI22910190T FI4455140T3 FI 4455140 T3 FI4455140 T3 FI 4455140T3 FI 22910190 T FI22910190 T FI 22910190T FI 4455140 T3 FI4455140 T3 FI 4455140T3
Authority
FI
Finland
Prior art keywords
methyl
compound
oxetan
dihydrobenzo
dioxan
Prior art date
Application number
FIEP22910190.2T
Other languages
English (en)
Finnish (fi)
Inventor
Gujun Xu
Weidong Lu
Junran Yang
Zhenxing Du
Qiyun Shao
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of FI4455140T3 publication Critical patent/FI4455140T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP22910190.2T 2021-12-23 2022-12-23 Glp-1-reseptoriagonistin kiteisiä muotoja ja niiden valmistusmenetelmiä FI4455140T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111586541 2021-12-23
PCT/CN2022/141407 WO2023116879A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
FI4455140T3 true FI4455140T3 (fi) 2026-05-28

Family

ID=86901327

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22910190.2T FI4455140T3 (fi) 2021-12-23 2022-12-23 Glp-1-reseptoriagonistin kiteisiä muotoja ja niiden valmistusmenetelmiä

Country Status (15)

Country Link
US (1) US20250049778A1 (cg-RX-API-DMAC7.html)
EP (2) EP4455140B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547112A (cg-RX-API-DMAC7.html)
KR (1) KR20240125004A (cg-RX-API-DMAC7.html)
CN (1) CN118401518A (cg-RX-API-DMAC7.html)
AU (1) AU2022422997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241677A1 (cg-RX-API-DMAC7.html)
DK (1) DK4455140T3 (cg-RX-API-DMAC7.html)
ES (1) ES3070919T3 (cg-RX-API-DMAC7.html)
FI (1) FI4455140T3 (cg-RX-API-DMAC7.html)
MX (1) MX2024007907A (cg-RX-API-DMAC7.html)
PL (1) PL4455140T3 (cg-RX-API-DMAC7.html)
PT (1) PT4455140T (cg-RX-API-DMAC7.html)
TW (1) TW202328115A (cg-RX-API-DMAC7.html)
WO (1) WO2023116879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EP4130005A4 (en) * 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
PT4157832T (pt) * 2020-05-27 2024-07-30 Qilu Regor Therapeutics Inc Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos
JP7812052B2 (ja) * 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
PT4455140T (pt) 2026-05-22
CA3241677A1 (en) 2023-06-29
DK4455140T3 (da) 2026-05-26
EP4455140A4 (en) 2025-04-09
PL4455140T3 (pl) 2026-06-29
EP4455140A1 (en) 2024-10-30
US20250049778A1 (en) 2025-02-13
EP4725484A2 (en) 2026-04-15
AU2022422997A1 (en) 2024-07-11
MX2024007907A (es) 2024-07-12
CN118401518A (zh) 2024-07-26
JP2024547112A (ja) 2024-12-26
TW202328115A (zh) 2023-07-16
EP4455140B1 (en) 2026-04-01
KR20240125004A (ko) 2024-08-19
WO2023116879A1 (zh) 2023-06-29
EP4725484A3 (en) 2026-06-10
ES3070919T3 (en) 2026-06-18